Methylprednisolone Tablet
Phase 2/3UNKNOWN 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hand Injuries
Conditions
Hand Injuries, Finger Injuries
Trial Timeline
Sep 1, 2021 → Sep 1, 2023
NCT ID
NCT05003596About Methylprednisolone Tablet
Methylprednisolone Tablet is a phase 2/3 stage product being developed by Johnson & Johnson for Hand Injuries. The current trial status is unknown. This product is registered under clinical trial identifier NCT05003596. Target conditions include Hand Injuries, Finger Injuries.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05003596 | Phase 2/3 | UNKNOWN |
Competing Products
17 competing products in Hand Injuries
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| tocilizumab + saline solution | Roche | Phase 3 | 77 |
| denosumab + Placebo | Amgen | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| clobetasol propionate | GSK plc | Approved | 84 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 2 | 49 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |